Skip to content

Phase II Trial of Balloon Occluded Transarterial Chemoembolization with Epirubicin and Ethiodized Oil for Multiple Advanced Hepatocellular Carcinomas of the Barcelona Clinic Liver Cancer Stage B

Phase II Trial of Balloon Occluded Transarterial Chemoembolization with Epirubicin and Ethiodized Oil for Multiple Advanced Hepatocellular Carcinomas of the Barcelona Clinic Liver Cancer Stage B - B-TACE Multiple Study

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000013868
Enrollment
51
Registered
2014-05-06
Start date
2014-05-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Sponsors

Department of Radiology, Juntendo University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Histologically or clinically diagnosed as hepatocellular carcinoma (HCC). 2) No prospective candidate for hepatectomy, local ablation therapy or liver transplantation. 3) Tumor size < 5cm, and tumor number 5 or less. 4) Advanced HCC (BCLC stage-B). 5) Child-Pugh score 7 or lower. 6) Age of 20 years or older. 7) ECOG Performance Status of 0. 8) Existence of mesurable lesion by modified RECIST. 9) At least 4 weeks passed after the previous therapy of hepatectomy, local ablation therapy or TACE. 10) No major organ failure and all the laboratory data, below are conserved. 11) At least 3 months survival expected. 12) Written informed consent obtained from the patient.

Exclusion criteria

Exclusion criteria: 1) Extrahepatic metastasis. 2) Diagnostic or suspicious lesion of Portal venous invasion, hepatic venous invasion or bile duct invasion. 3) Post ruputred state of hepatocellular carcinoma 4) Remarkable arterio-portal or arterio-venous shunting. 5) Hepatic artery occlusion or major extrahepatic collaterals interfering effective drug delivery. 6) Post biliary reconstruction state. 7) Refractory ascites or pleural effusion. 8) Comorbid diseases as cardiac failure, renal failure, active infection, active gastrointestinal bleeding, active associated cancers, hepatic encephalopathy or uncontrolled psychologic disorders. 9) Fever (more than 38 degrees Celsius) 10) Allergy to contrast media or anthracycline agents. 11) Pregnant or lactating. 12) Other reasons not indicated to this study judged by doctors.

Design outcomes

Primary

MeasureTime frame
Response Rate

Secondary

MeasureTime frame
Frequency and levels of adverse effects, change of tumor markers, overall survival, 1-year survival rate, 2-year survival rate, progression free survival

Countries

Japan

Contacts

Public ContactMasahiro Horikawa

Juntendo University Hospital Department of Radiology

horikawaradivr@gmail.com03-5802-1230

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026